# Sana Biotechnology, Inc.: financial statements, quarterly

SANA · Nasdaq · CIK 1770121 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sana.md) · [Financials](/companies/sana/financials.md) · [Filings](/companies/sana/filings.md) · [Insiders](/companies/sana/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sana/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [65.6](/filings/0000950170-24-123730.md) | [56.0 d](/filings/0001193125-26-088215.md) | [56.4](/filings/0000950170-25-066943.md) | [60.9](/filings/0001770121-25-000010.md) | [53.2](/filings/0001193125-25-269569.md) | [45.1 d](/filings/0001193125-26-088215.md) | [37.2](/filings/0001193125-26-216769.md) | [29.8](/filings/0001193125-26-342395.md) | [30.1](/filings/0001193125-25-269569.md) | [34.9 d](/filings/0001193125-26-088215.md) | [28.7](/filings/0001193125-26-216769.md) | [30.7](/filings/0001193125-26-342395.md) |
| Operating income | $m | [(2.2)](/filings/0000950170-24-123730.md) | [(90.6) d](/filings/0001193125-26-088215.md) | [(111)](/filings/0000950170-25-066943.md) | [(49.4)](/filings/0001770121-25-000010.md) | [(61.8)](/filings/0001193125-25-269569.md) | [(50.9) d](/filings/0001193125-26-088215.md) | [(50.6)](/filings/0001193125-26-216769.md) | [(95.0)](/filings/0001193125-26-342395.md) | [(43.5)](/filings/0001193125-25-269569.md) | [(61.2) d](/filings/0001193125-26-088215.md) | [(48.6)](/filings/0001193125-26-216769.md) | [(65.4)](/filings/0001193125-26-342395.md) |
| Net income | $m | [1.0](/filings/0000950170-24-123730.md) | [(88.1) d](/filings/0001193125-26-088215.md) | [(107)](/filings/0001193125-25-269569.md) | [(50.3)](/filings/0001193125-25-269569.md) | [(59.9)](/filings/0001193125-25-269569.md) | [(49.1) d](/filings/0001193125-26-088215.md) | [(49.4)](/filings/0001193125-26-342395.md) | [(93.8)](/filings/0001193125-26-342395.md) | [(42.2)](/filings/0001193125-25-269569.md) | [(58.8) d](/filings/0001193125-26-088215.md) | [(47.2)](/filings/0001193125-26-342395.md) | [(63.6)](/filings/0001193125-26-342395.md) |
| Diluted EPS | $ per share | [0.00](/filings/0000950170-24-123730.md) | not reported | [(0.49)](/filings/0000950170-25-066943.md) | [(0.21)](/filings/0001770121-25-000010.md) | [(0.25)](/filings/0001193125-25-269569.md) | not reported | [(0.21)](/filings/0001193125-26-216769.md) | [(0.39)](/filings/0001193125-26-342395.md) | [(0.16)](/filings/0001193125-25-269569.md) | not reported | [(0.17)](/filings/0001193125-26-216769.md) | [(0.22)](/filings/0001193125-26-342395.md) |
| Basic EPS | $ per share | [0.00](/filings/0000950170-24-123730.md) | not reported | [(0.49)](/filings/0000950170-25-066943.md) | [(0.21)](/filings/0001770121-25-000010.md) | [(0.25)](/filings/0001193125-25-269569.md) | not reported | [(0.21)](/filings/0001193125-26-216769.md) | [(0.39)](/filings/0001193125-26-342395.md) | [(0.16)](/filings/0001193125-25-269569.md) | not reported | [(0.17)](/filings/0001193125-26-216769.md) | [(0.22)](/filings/0001193125-26-342395.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [168](/filings/0000950170-23-061171.md) | [134](/filings/0001193125-26-088215.md) | [177](/filings/0000950170-24-055727.md) | [135](/filings/0000950170-24-094052.md) | [127](/filings/0000950170-24-123730.md) | [128](/filings/0001193125-26-088215.md) | [96.1](/filings/0000950170-25-066943.md) | [71.3](/filings/0001770121-25-000010.md) | [103](/filings/0001193125-25-269569.md) | [71.9](/filings/0001193125-26-342395.md) | [83.8](/filings/0001193125-26-216769.md) | [57.1](/filings/0001193125-26-342395.md) |
| Current assets | $m | [280](/filings/0000950170-23-061171.md) | [214](/filings/0000950170-25-040254.md) | [321](/filings/0000950170-24-055727.md) | [263](/filings/0000950170-24-094052.md) | [210](/filings/0000950170-24-123730.md) | [161](/filings/0001193125-26-088215.md) | [113](/filings/0000950170-25-066943.md) | [82.5](/filings/0001770121-25-000010.md) | [162](/filings/0001193125-25-269569.md) | [149](/filings/0001193125-26-342395.md) | [112](/filings/0001193125-26-216769.md) | [171](/filings/0001193125-26-342395.md) |
| Total assets | $m | [631](/filings/0000950170-23-061171.md) | [565](/filings/0000950170-25-040254.md) | [681](/filings/0000950170-24-055727.md) | [619](/filings/0000950170-24-094052.md) | [559](/filings/0000950170-24-123730.md) | [501](/filings/0001193125-26-088215.md) | [445](/filings/0000950170-25-066943.md) | [362](/filings/0001770121-25-000010.md) | [435](/filings/0001193125-25-269569.md) | [417](/filings/0001193125-26-342395.md) | [374](/filings/0001193125-26-216769.md) | [432](/filings/0001193125-26-342395.md) |
| Current liabilities | $m | [66.6](/filings/0000950170-23-061171.md) | [64.5](/filings/0000950170-25-040254.md) | [52.9](/filings/0000950170-24-055727.md) | [50.7](/filings/0000950170-24-094052.md) | [47.0](/filings/0000950170-24-123730.md) | [45.4](/filings/0001193125-26-088215.md) | [33.2](/filings/0000950170-25-066943.md) | [33.4](/filings/0001770121-25-000010.md) | [35.5](/filings/0001193125-25-269569.md) | [78.7](/filings/0001193125-26-342395.md) | [86.3](/filings/0001193125-26-216769.md) | [124](/filings/0001193125-26-342395.md) |
| Total liabilities | $m | [266](/filings/0000950170-23-061171.md) | [278](/filings/0000950170-25-040254.md) | [306](/filings/0000950170-24-055727.md) | [279](/filings/0000950170-24-094052.md) | [267](/filings/0000950170-24-123730.md) | [251](/filings/0001193125-26-088215.md) | [236](/filings/0000950170-25-066943.md) | [239](/filings/0001770121-25-000010.md) | [240](/filings/0001193125-25-269569.md) | [256](/filings/0001193125-26-342395.md) | [254](/filings/0001193125-26-216769.md) | [277](/filings/0001193125-26-342395.md) |
| Shareholders' equity | $m | [366](/filings/0000950170-24-123730.md) | [288](/filings/0001193125-26-088215.md) | [375](/filings/0001193125-25-269569.md) | [340](/filings/0001193125-25-269569.md) | [292](/filings/0001193125-25-269569.md) | [251](/filings/0001193125-26-342395.md) | [209](/filings/0001193125-26-342395.md) | [123](/filings/0001193125-26-342395.md) | [195](/filings/0001193125-25-269569.md) | [161](/filings/0001193125-26-342395.md) | [119](/filings/0001193125-26-342395.md) | [155](/filings/0001193125-26-342395.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(63.6) d](/filings/0000950170-24-123730.md) | [(52.0) d](/filings/0001193125-26-088215.md) | [(65.6)](/filings/0000950170-25-066943.md) | [(58.5) d](/filings/0001770121-25-000010.md) | [(51.8) d](/filings/0001193125-25-269569.md) | [(47.2) d](/filings/0001193125-26-088215.md) | [(48.7)](/filings/0001193125-26-216769.md) | [(33.1) d](/filings/0001193125-26-342395.md) | [(29.4) d](/filings/0001193125-25-269569.md) | [(32.6) d](/filings/0001193125-26-088215.md) | [(37.4)](/filings/0001193125-26-216769.md) | [(32.8) d](/filings/0001193125-26-342395.md) |
| Capital expenditure | $m | [2.2 d](/filings/0000950170-24-123730.md) | [14.0 d](/filings/0001193125-26-088215.md) | [15.8](/filings/0000950170-25-066943.md) | [13.1 d](/filings/0001770121-25-000010.md) | [4.1 d](/filings/0001193125-25-269569.md) | [0.4 d](/filings/0001193125-26-088215.md) | [0.1](/filings/0001193125-26-216769.md) | [(0.1) d](/filings/0001193125-26-342395.md) | [0.0 d](/filings/0001193125-25-269569.md) | [0.9 d](/filings/0001193125-26-088215.md) | [0.3](/filings/0001193125-26-216769.md) | [1.6 d](/filings/0001193125-26-342395.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [189](/filings/0000950170-23-061171.md) | [191](/filings/0000950170-24-055727.md) | [193](/filings/0000950170-24-094052.md) | [200](/filings/0000950170-24-123730.md) | [217](/filings/0000950170-25-066943.md) | [234](/filings/0001770121-25-000010.md) | [235](/filings/0001193125-25-269569.md) | [238](/filings/0001193125-26-216769.md) | [238](/filings/0001193125-26-342395.md) | [260](/filings/0001193125-25-269569.md) | [277](/filings/0001193125-26-216769.md) | [296](/filings/0001193125-26-342395.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 299,360,637 at 2026-08-03, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-342395.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.